Abstract Body

Background

Urine tenofovir (TFV) and viral load (VL) assays performed at the point of care (POC) could improve HIV treatment outcomes, but have not been assessed together in randomized trials. We tested whether monthly POC urine TFV testing and biannual POC VL testing improved viral suppression and retention-in-care among people with HIV (PWH) initiating TFV-based antiretroviral therapy (ART).

Methods

We recruited PWH initiating first-line ART at three South African public clinics between 02/2021-06/2023. Participants were randomized 1:1 to the intervention (monthly urine TFV testing with adherence counselling for the first 5 months; POC VL testing at Month 6 and 12 with reflex urine TFV testing for VL >200 copies/mL and HIV drug resistance testing if TFV test indicated adherence) or control arm (routine adherence counselling and lab-based VL testing). The primary outcome was a composite of viral suppression (<200 copies/ml) and retention-in-care at 72 weeks after ART initiation. The secondary outcome was intracellular TFV-diphosphate concentrations in dried blood spots using liquid chromatography/tandem mass spectrometry. The trial was powered to identify a 10% increase (75% vs 85%) in the composite outcome; intention-to-treat analyses estimated the relative risks of achieving outcomes in the intervention arm, as compared to the control arm.

Results

Of 539 participants enrolled, 58% were female, mean age 33 years, mean CD4 count 393 cells/µl, and median VL 38,027 copies/ml. At 72 weeks, 186/270 (69%) intervention and 167/269 (62%) control arm participants were retained-in-care with viral suppression (relative risk=1.10; 95% CI 0.97-1.24; p=0.12). Both retained-in-care (74.1% vs 69.1%; p=0.21) and VL suppression among those retained (93.0% vs 90.3%; p=0.34) favored the intervention arm, but were not statistically significant. At 72 weeks, the geometric mean titer of TFV-diphosphate was similar between study arms (723 vs 818 fmol/punch; p=0.13). Acceptability by participants and feasibility assessed by providers of the POC testing in the intervention arm were both high.

Conclusions

Among PWH initiating TFV-based ART in South African public clinics, more than 90% achieved VL suppression among those retained (less than 75%). Monthly POC urine TFV and biannual POC VL testing did not significantly improve viral suppression and retention-in-care, indicating that additional interventions are needed to reach 95% targets and improve retention.